Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patie…
Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
Transactions 2026-05-29 Financing
Report of exempt distribution (45-106F1).pdf
Transactions 2026-05-19 Financing
Resverlogix Closes US$2 Million Shares-for-Interest Private Placement
News release - English.pdf
Results 2026-05-15
Interim financial statements/report – English.pdf
Results 2026-05-15
Interim MD&A - English.pdf
Transactions 2026-05-11 Financing
Resverlogix Announces One-Year Extension of Debenture
News release - English.pdf
Results 2026-04-11
Annual information form - English.pdf
Results 2026-04-11
Annual MD&A - English.pdf
Results 2026-04-10
Audited annual financial statements – English.pdf
News 2026-02-27
Report of exempt distribution (45-106F1).pdf
Transactions 2026-02-19 Financing
Resverlogix Closes $2.8 Million Shares-for-Interest Private Placement
News release - English.pdf
Results 2025-11-13 Financials
Interim financial statements/report – English.pdf
Results 2025-11-13 Financials
Interim MD&A - English.pdf
Results 2025-08-14 Financials
Interim financial statements/report – English.pdf
Results 2025-08-14 Financials
Interim MD&A - English.pdf
News 2025-06-30
News release - English.pdf